← Back to Search

Behavioural Intervention

Provider Training and Patient Education for HIV Prevention (MOST:PrEP Trial)

N/A
Waitlist Available
Led By Elizabeth Lockhart, PhD
Research Sponsored by Henry Ford Health System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up year 1 and year 5 electronic health record data pull.
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to improve the rate of new PrEP prescriptions at a healthcare system by testing different intervention components, such as training for providers and patient education, in primary care settings. The goal is to

Who is the study for?
This trial is for primary care providers and patients at Henry Ford Health System. Providers must be over 18, able to prescribe in Michigan, and work at HFH. Patients also need to be over 18, have an EHR account, see a HFH provider during the study, and meet criteria for PrEP but not already be on it or HIV positive.
What is being tested?
The trial tests how effective different interventions are in increasing new PrEP prescriptions in primary care. Interventions include alerts for providers and training simulations, as well as risk assessments and informational videos about PrEP for patients. The goal is to find efficient ways to prevent HIV.
What are the potential side effects?
Since this trial focuses on educational tools rather than medications, there aren't direct side effects like with drug trials. However, participants may experience discomfort or privacy concerns when discussing personal health information.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~year 1 and year 5 electronic health record data pull.
This trial's timeline: 3 weeks for screening, Varies for treatment, and year 1 and year 5 electronic health record data pull. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Clinic-Level PrEP Prescription
Secondary study objectives
Perceived HIV risk
PrEP Knowledge
PrEP awareness
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

16Treatment groups
Experimental Treatment
Active Control
Group I: VideoExperimental Treatment1 Intervention
Patient PrEP Video only
Group II: Training, Risk Assessment, and VideoExperimental Treatment3 Interventions
Provider Training, Patient Risk Assessment, and Patient PrEP Video
Group III: Training, Best Practice Alert, and VideoExperimental Treatment3 Interventions
Provider Training, Best Practice Alert, and Patient PrEP Video
Group IV: Training, Best Practice Alert, and Risk AssessmentExperimental Treatment3 Interventions
Provider Training, Best Practice Alert, and Patient Risk Assessment
Group V: Training, Best Practice Alert, Risk Assessment, and VideoExperimental Treatment4 Interventions
Provider Training, Best Practice Alert, Patient Risk Assessment, and Patient PrEP Video
Group VI: Training and VideoExperimental Treatment2 Interventions
Provider Training and Patient PrEP Video
Group VII: Training and Risk AssessmentExperimental Treatment2 Interventions
Provider Training and Patient Risk Assessment
Group VIII: Training and Best Practice AlertExperimental Treatment2 Interventions
Provider Training and Best Practice Alert
Group IX: TrainingExperimental Treatment1 Intervention
Provider Training
Group X: Risk Assessment and VideoExperimental Treatment2 Interventions
Patient Risk Assessment and Patient PrEP Video
Group XI: Risk AssessmentExperimental Treatment1 Intervention
Patient Risk Assessment only
Group XII: Best Practice Alert, Risk Assessment and VideoExperimental Treatment3 Interventions
Best Practice Alert, Patient Risk Assessment, and Patient PrEP Video
Group XIII: Best Practice Alert and VideoExperimental Treatment2 Interventions
Best Practice Alert and Patient PrEP Video
Group XIV: Best Practice Alert and Risk AssessmentExperimental Treatment1 Intervention
Best Practice Alert and Patient Risk Assessment
Group XV: Best Practice AlertExperimental Treatment1 Intervention
Best Practice Alert only
Group XVI: No interventionActive Control1 Intervention
No intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Best Practice Alert
2019
N/A
~14550

Find a Location

Who is running the clinical trial?

New York UniversityOTHER
240 Previous Clinical Trials
218,899 Total Patients Enrolled
Henry Ford Health SystemLead Sponsor
311 Previous Clinical Trials
2,174,986 Total Patients Enrolled
University of South FloridaOTHER
426 Previous Clinical Trials
190,689 Total Patients Enrolled
~920 spots leftby Apr 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top